To access the full text documents, please follow this link: http://hdl.handle.net/2445/119442

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.
Llufriu Duran, Sara; Sepúlveda, María; Blanco, Yolanda; Marín, Pedro; Moreno, Beatriz; Berenguer, Joan; Gabilondo, Iñigo; Martínez Heras, Eloy; Sola Valls, Nuria; Arnaiz Gargallo, Juan Alberto; Andreu, Enrique J.; Fernández, Begoña; Bullich Roig, Santiago; Sánchez Dalmau, Bernardo; Graus Ribas, Francesc; Villoslada, Pablo; Saiz Hinajeros, Albert
Universitat de Barcelona
OBJECTIVE: Uncontrolled studies of mesenchymal stem cells (MSCs) in multiple sclerosis suggested some beneficial effect. In this randomized, double-blind, placebo-controlled, crossover phase II study we investigated their safety and efficacy in relapsing-remitting multiple sclerosis patients. Efficacy was evaluated in terms of cumulative number of gadolinium-enhancing lesions (GEL) on magnetic resonance imaging (MRI) at 6 months and at the end of the study. METHODS: Patients unresponsive to conventional therapy, defined by at least 1 relapse and/or GEL on MRI scan in past 12 months, disease duration 2 to 10 years and Expanded Disability Status Scale (EDSS) 3.0-6.5 were randomized to receive IV 1-2×10(6) bone-marrow-derived-MSCs/Kg or placebo. After 6 months, the treatment was reversed and patients were followed-up for another 6 months. Secondary endpoints were clinical outcomes (relapses and disability by EDSS and MS Functional Composite), and several brain MRI and optical coherence tomography measures. Immunological tests were explored to assess the immunomodulatory effects. RESULTS: At baseline 9 patients were randomized to receive MSCs (n = 5) or placebo (n = 4). One patient on placebo withdrew after having 3 relapses in the first 5 months. We did not identify any serious adverse events. At 6 months, patients treated with MSCs had a trend to lower mean cumulative number of GEL (3.1, 95% CI = 1.1-8.8 vs 12.3, 95% CI = 4.4-34.5, p = 0.064), and at the end of study to reduced mean GEL (-2.8±5.9 vs 3±5.4, p = 0.075). No significant treatment differences were detected in the secondary endpoints. We observed a non-significant decrease of the frequency of Th1 (CD4+ IFN-γ+) cells in blood of MSCs treated patients. CONCLUSION: Bone-marrow-MSCs are safe and may reduce inflammatory MRI parameters supporting their immunomodulatory properties. ClinicalTrials.gov NCT01228266.
Cèl·lules mare
Esclerosi múltiple
Ressonància magnètica
Cèl·lules T
Cèl·lules B
Assaigs clínics
Stem cells
Multiple sclerosis
Magnetic resonance
T cells
B cells
Clinical trials
cc-by (c) Llufriu Duran, Sara et al., 2014
http://creativecommons.org/licenses/by/3.0/es
Article
info:eu-repo/semantics/publishedVersion
Public Library of Science (PLoS)
         

Show full item record

Related documents

Other documents of the same author

Llufriu Duran, Sara; Sepúlveda, María; Blanco, Yolanda; Marín, Pedro; Moreno, Beatriz; Berenguer, Joan; Gabilondo, Iñigo; Martínez Heras, Eloy; Sola Valls, Nuria; Arnaiz Gargallo, Juan Alberto; Andreu, Enrique J.; Fernández, Begoña; Bullich Roig, Santiago; Sánchez Dalmau, Bernardo; Graus Ribas, Francesc; Villoslada, Pablo; Saiz Hinajeros, Albert
Llufriu Duran, Sara; Sepúlveda, María; Blanco, Yolanda; Marín, Pedro; Moreno, Beatriz; Berenguer, Joan; Gabilondo, Iñigo; Martínez Heras, Eloy; Sola Valls, Nuria; Arnaiz Gargallo, Juan Alberto; Andreu, Enrique J.; Fernández, Begoña; Bullich Roig, Santiago; Sánchez Dalmau, Bernardo; Graus Ribas, Francesc; Villoslada, Pablo; Saiz Hinajeros, Albert
Hernández Martinez Lapiscina, Elena; Fraga Pumar, Elena; Gabilondo, Iñigo; Martínez Heras, Eloy; Torres Torres, Ruben; Ortiz Pérez, Santiago; Llufriu Duran, Sara; Tercero, Ana; Andorra, Magi; Figueras Roca, Marc; Lampert, Erika; Zubizarreta, Irati; Saiz Hinajeros, Albert; Sánchez Dalmau, Bernardo; Villoslada, Pablo
Martínez Heras, Eloy; Varriano, F.; Prč; kovska, V.; Laredo, C.; Andorra, Magi; Martínez Lapiscina, Elena H.; Calvo, Anna; Lampert, Erika; Villoslada, Pablo; Saiz Hinajeros, Albert; Prats Galino, Alberto; Llufriu Duran, Sara
Sepúlveda, Maria; Armangué, Thaís; Sola Valls, Nuria; Arrambide, Georgina; Meca Lallana, José E.; Oreja Guevara, Celia; Mendibe, Mar; Alvarez de Arcaya, Amaya; Aladro, Yolanda; Casanova, Bonaventura; Olascoaga, Javier; Jiménez Huete, Adolfo; Fernández Fournier, Mireya; Ramió i Torrentà, Lluís; Cobo Calvo, Alvaro; Viñals, Montserrat; Andrés, Clara de; Meca Lallana, Virginia; Cervelló, Angeles; Calles, Carmen; Barón Rubio, Manuel; Ramo Tello, Cristina; Caminero, Ana; Munteis, Elvira; Antigüedad, Alfredo R.; Blanco, Yolanda; Villoslada, Pablo; Montalban Gairín, Xavier; Graus, Francesc; Saiz, Albert; NMO Study Group
 

Coordination

 

Supporters